BCPC BALCHEM CORP
Chemicals & Allied Products · Nasdaq · SEC CIK 9326 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.4%
TTM net income YoY14.5%
TTM EPS YoY16.2%
Revenue 3-yr CAGR6.2%
Net income 3-yr CAGR18.3%
Margins
Gross margin36.5%
Operating margin20.7%
Net margin15.4%
FCF margin—
EBITDA margin25.1%
Returns
ROE13.0%
ROA10.2%
ROIC (approx.)14.3%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.00x
Current ratio2.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio-3.1%
Payout ratio18.0%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.04B | $953.68M | $922.44M | $942.36M | $799.02M |
| Cost of revenue | $666.53M | $617.48M | $620.38M | $661.91M | $555.85M |
| Gross profit | $370.63M | $336.21M | $302.06M | $280.45M | $243.17M |
| R&D expense | $18.51M | $16.79M | $15.05M | $12.19M | $13.52M |
| SG&A expense | $67.42M | $67.59M | $53.42M | $55.66M | $41.73M |
| Operating income | $209.33M | $182.91M | $159.19M | $145.19M | $127.50M |
| Pretax income | $199.03M | $166.45M | $137.26M | $133.75M | $125.23M |
| Income tax | $44.19M | $37.98M | $28.72M | $28.38M | $29.13M |
| Net income | $154.84M | $128.47M | $108.54M | $105.37M | $96.10M |
| EBITDA | $255.02M | $230.88M | $214.13M | $197.03M | $176.38M |
| EPS (basic) | 4.80 | 3.97 | 3.38 | 3.29 | 2.98 |
| EPS (diluted) | 4.75 | 3.93 | 3.35 | 3.25 | 2.94 |
| Dividends declared per share | 0.96 | 0.87 | 0.79 | 0.71 | — |
| Weighted avg. shares (diluted) | 32.60M | 32.72M | 32.45M | 32.39M | 32.67M |
| Banking | |||||
| Net interest income | — | — | -$22.61M | -$10.27M | -$2.46M |
| Balance sheet | |||||
| Cash & equivalents | $74.57M | $49.52M | $64.45M | $66.56M | $103.24M |
| Receivables | $143.60M | $119.66M | $125.28M | $131.58M | $117.41M |
| Inventory | $131.45M | $130.80M | $109.52M | $119.67M | $91.06M |
| Current assets | $365.61M | $313.77M | $314.24M | $335.80M | $322.23M |
| PP&E, net | $306.65M | $282.15M | $276.04M | $271.36M | $237.52M |
| Goodwill | $816.38M | $780.03M | $778.91M | $769.51M | $523.95M |
| Intangibles | $132.99M | $132.48M | $191.21M | $213.29M | $94.67M |
| Total assets | $1.69B | $1.58B | $1.60B | $1.62B | $1.20B |
| Current liabilities | $176.38M | $157.69M | $148.49M | $140.04M | $143.80M |
| Total liabilities | $428.84M | $425.46M | $543.23M | $686.23M | $322.31M |
| Shareholders' equity | $1.26B | $1.15B | $1.05B | $938.28M | $877.01M |
| Shares outstanding | 32.06M | 32.53M | 32.25M | 32.15M | 32.29M |
| Cash flow statement | |||||
| Operating cash flow | $216.56M | $182.00M | $183.76M | $138.54M | $160.51M |
| Capital expenditure | — | — | — | $49.09M | $36.14M |
| Free cash flow | — | — | — | $89.45M | $124.37M |
| Investing cash flow | -$43.89M | -$59.74M | -$34.81M | -$416.01M | -$35.30M |
| Financing cash flow | -$152.81M | -$133.81M | -$153.32M | $246.68M | -$102.18M |
| Depreciation & amortization | $45.69M | $47.97M | $54.94M | $51.85M | $48.88M |
| Stock-based compensation | $18.06M | $16.68M | $16.05M | $13.22M | $10.80M |
| Dividends paid | $28.29M | $25.58M | $22.87M | $20.71M | $18.72M |
| Share buybacks | $107.64M | $5.68M | $4.47M | $35.42M | $35.24M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.